Navigation Links
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
Date:12/4/2007

SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.

"Recent changes to the American Diabetes Association guidelines highlight the diabetic's increased risk for coronary artery disease (CAD)," according to MedPredict's President Jeff Berk. "In light of these guidelines, our Panel provides insight into unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."

Also discussed:

-- Incretins will dominate new launches for HbA1c lowering drugs for the

next few years. The Panel discusses the significance of targeting

DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.

Strengths and weaknesses of new monotherapies and combination

approaches are discussed.

-- These new orals and parenterals will put pressure on established

products, including metformin, sulfonylureas and TZDs. The Panel

offers insight into how each fits into the diabetes / CAD paradigm.

-- The Panel describes why Exubera has failed commercially, and

benchmarks next-generation insulins.

-- While still very early in development, the Panel shared key insights

about the future for inhibition of SGLT.

Key products mentioned in this report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), Exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo Nordisk/Aradigm), Oral-lyn (Generex/Lilly), buccal insulin (GSK).

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: